860812P

12:0(2S-OH) Ceramide

Avanti Research^™ - A Croda Brand 860812P, powder

• Synonym(e): N-(2′-(S)-hydroxylauroyl)-D-erythro-sphingosine
• Empirische Formel (Hill-System): C₃₀H₅₉NO₄
• CAS-Nummer: 1246298-45-2
• Molekulargewicht: 497.79
• MDL-Nummer: MFCD22416670
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 5 mg (860812P-5mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 860812P
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC([C@@H](O)CCCCCCCCCC)=O)CO
• InChI: 1S/C30H59NO4/c1-3-5-7-9-11-13-14-15-16-17-19-20-22-24-28(33)27(26-32)31-30(35)29(34)25-23-21-18-12-10-8-6-4-2/h22,24,27-29,32-34H,3-21,23,25-26H2,1-2H3,(H,31,35)/b24-22+/t27-,28+,29-/m0/s1
• InChIKey: CPDJNFOAARXMMT-NGXZUFBYSA-N

Beschreibung

Allgemeine Beschreibung

Ceramides with 2-hydroxy fatty acids (hFA) group are present in the epidermis. 12:0(2S-OH) Ceramide is a 2S hydroxylated lauric acid-containing ceramide.

Biochem./physiol. Wirkung

Hydroxy fatty acid (hFA)-sphingolipids facilitate cell signaling. hFA-ceramides contribute to the permeability barrier function of the epidermis. Synthesis of hFA-ceramides are catalyzed by fatty acid 2-hydroxylase (FA2H). Mutations of FA2H causes nervous system disorders leukodystrophy and spastic paraparesis in humans. An antitumor drug, PM02734 requires hFA-ceramides in the cell membrane to exhibit its activity.

Verpackung

5 mL Amber Glass Screw Cap Vial (860812P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3